Hansoh Pharmaceutical Group（HNSP.F）株式概要投資持株会社である漢創薬集団有限公司は、中華人民共和国において医薬品の研究・開発・製造・販売を行っている。 詳細HNSP.F ファンダメンタル分析スノーフレーク・スコア評価3/6将来の成長1/6過去の実績5/6財務の健全性5/6配当金2/6報酬当社が推定した公正価値より37.4%で取引されている 収益は年間10.83%増加すると予測されています 過去1年間で収益は27.1%増加しました アナリストらは、株価が38%上昇するだろうとほぼ一致している。 リスク分析株式の流動性は非常に低い すべてのリスクチェックを見るHNSP.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$4.492.8% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture026b2016201920222025202620282031Revenue CN¥25.5bEarnings CN¥9.4bAdvancedSet Fair ValueView all narrativesHansoh Pharmaceutical Group Company Limited 競合他社ZoetisSymbol: NYSE:ZTSMarket cap: US$34.1bRoyalty PharmaSymbol: NasdaqGS:RPRXMarket cap: US$31.4bTeva Pharmaceutical IndustriesSymbol: NYSE:TEVAMarket cap: US$39.7bHisamitsu PharmaceuticalSymbol: OTCPK:HTSU.YMarket cap: US$8.2b価格と性能株価の高値、安値、推移の概要Hansoh Pharmaceutical Group過去の株価現在の株価HK$4.4952週高値HK$5.2052週安値HK$3.54ベータ0.551ヶ月の変化-13.00%3ヶ月変化n/a1年変化66.26%3年間の変化n/a5年間の変化n/aIPOからの変化145.30%最新ニュースお知らせ • Mar 18Hansoh Pharmaceutical Group Company Limited to Report Fiscal Year 2025 Results on Mar 29, 2026Hansoh Pharmaceutical Group Company Limited announced that they will report fiscal year 2025 results at 9:30 AM, China Standard Time on Mar 29, 2026お知らせ • Feb 21Hansoh Pharmaceutical Group Company Limited Announces Approval in the European Union as MonotherapyThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, on February 12, 2026, Aumolertinib Mesylate Tablets, marketed as Ameile in China and Aumseqa outside China, the Group's innovative drug, has been approved in the European Union as monotherapy for: (i) the first-line treatment of adult patients with advanced non-small cell lung cancer ("NSCLC") whose tumours have epidermal growth factor receptor ("EGFR") exon 19 deletions or exon 21 (L858R) substitution mutations; and (ii) the treatment of adult patients with advanced EGFR T790M mutation-positive NSCLC. The approval by the European Commission (EC) follows the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).お知らせ • Jan 08Hansoh Pharmaceutical Group Company Limited Announces Drug Registration Approval of the Fifth Indication of Ameile (Aumolertinib Mesylate Tablets) Was Granted by the National Medical Products AdministrationThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, the Group's innovative drug Ameile (Aumolertinib Mesylate Tablets) has been granted drug registration approval by the National Medical Products Administration (" NMPA") of China, approving the addition of an indication: Ameile in combination with pemetrexed and platinum-based chemotherapy to be used as the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC") whose tumors have epidermal growth factor receptor (" EGFR") exon 19 deletions or exon 21 (L858R) mutations. This is the fifth indication of Ameile which has been approved.お知らせ • Aug 21Hansoh Pharmaceutical Group Company Limited has filed a Follow-on Equity Offering in the amount of HKD 3.9204 billion.Hansoh Pharmaceutical Group Company Limited has filed a Follow-on Equity Offering in the amount of HKD 3.9204 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 108,000,000 Price\Range: HKD 36.3 Transaction Features: Subsequent Direct Listingお知らせ • Aug 07Hansoh Pharmaceutical Group Company Limited to Report First Half, 2025 Results on Aug 18, 2025Hansoh Pharmaceutical Group Company Limited announced that they will report first half, 2025 results on Aug 18, 2025お知らせ • Jun 05Hansoh Pharmaceutical Group Company Limited Announces Approval of Aumolertinib Mesilate Tablets by the Medicines and Healthcare Products Regulatory Agency for MarketingThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, Aumolertinib Mesilate Tablets (trade name in the UK: Aumseqa®?), the Group's innovative drug, has been approved by the Medicines and Healthcare Products Regulatory Agency ("MHRA") in the UK for marketing. Aumseqa®? as monotherapy is indicated for: the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC") with activating epidermal growth factor receptor (" EGFR") mutations, and the treatment of adult patients with locally Advanced or metastatic EGFR T790M mutation-positive NSCLC.最新情報をもっと見るRecent updatesお知らせ • Mar 18Hansoh Pharmaceutical Group Company Limited to Report Fiscal Year 2025 Results on Mar 29, 2026Hansoh Pharmaceutical Group Company Limited announced that they will report fiscal year 2025 results at 9:30 AM, China Standard Time on Mar 29, 2026お知らせ • Feb 21Hansoh Pharmaceutical Group Company Limited Announces Approval in the European Union as MonotherapyThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, on February 12, 2026, Aumolertinib Mesylate Tablets, marketed as Ameile in China and Aumseqa outside China, the Group's innovative drug, has been approved in the European Union as monotherapy for: (i) the first-line treatment of adult patients with advanced non-small cell lung cancer ("NSCLC") whose tumours have epidermal growth factor receptor ("EGFR") exon 19 deletions or exon 21 (L858R) substitution mutations; and (ii) the treatment of adult patients with advanced EGFR T790M mutation-positive NSCLC. The approval by the European Commission (EC) follows the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).お知らせ • Jan 08Hansoh Pharmaceutical Group Company Limited Announces Drug Registration Approval of the Fifth Indication of Ameile (Aumolertinib Mesylate Tablets) Was Granted by the National Medical Products AdministrationThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, the Group's innovative drug Ameile (Aumolertinib Mesylate Tablets) has been granted drug registration approval by the National Medical Products Administration (" NMPA") of China, approving the addition of an indication: Ameile in combination with pemetrexed and platinum-based chemotherapy to be used as the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC") whose tumors have epidermal growth factor receptor (" EGFR") exon 19 deletions or exon 21 (L858R) mutations. This is the fifth indication of Ameile which has been approved.お知らせ • Aug 21Hansoh Pharmaceutical Group Company Limited has filed a Follow-on Equity Offering in the amount of HKD 3.9204 billion.Hansoh Pharmaceutical Group Company Limited has filed a Follow-on Equity Offering in the amount of HKD 3.9204 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 108,000,000 Price\Range: HKD 36.3 Transaction Features: Subsequent Direct Listingお知らせ • Aug 07Hansoh Pharmaceutical Group Company Limited to Report First Half, 2025 Results on Aug 18, 2025Hansoh Pharmaceutical Group Company Limited announced that they will report first half, 2025 results on Aug 18, 2025お知らせ • Jun 05Hansoh Pharmaceutical Group Company Limited Announces Approval of Aumolertinib Mesilate Tablets by the Medicines and Healthcare Products Regulatory Agency for MarketingThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, Aumolertinib Mesilate Tablets (trade name in the UK: Aumseqa®?), the Group's innovative drug, has been approved by the Medicines and Healthcare Products Regulatory Agency ("MHRA") in the UK for marketing. Aumseqa®? as monotherapy is indicated for: the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC") with activating epidermal growth factor receptor (" EGFR") mutations, and the treatment of adult patients with locally Advanced or metastatic EGFR T790M mutation-positive NSCLC.お知らせ • May 31Hansoh Pharmaceutical Group Company Limited Announces the Third Biologics License Application of Xin Yue (Inebilizumab Injection) Has Been Accepted by the National Medical Products AdministrationThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, on May 29, 2025, the third biologics license application ("BLA") of XINYUE (Xin Yue ®?) (Inebilizumab Injection) (the "Product") has been accepted by the National Medical Products Administration (the "NMPA"), which is for the treatment of generalized myasthenia gravis (gMG) in adult patients.お知らせ • May 30+ 1 more updateHansoh Pharmaceutical Group Company Limited Obtains Clinical Trial Approval Issued by the National Medical Products AdministrationThe board of directors of Hansoh Pharmaceutical Group Company Limited announce that, HS-10542 capsules, a Category 1 innovative drug self-developed by the Group, has obtained the Clinical Trial Approval issued by the National Medical Products Administration (NMPA) of China, which is intended to be investigated in clinical trials for paroxysmal nocturnal hemoglobinuria (PNH), and immunoglobulin A nephropathy (IgAN).お知らせ • May 29+ 1 more updateHansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 20, 2025Hansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 20, 2025, at 10:00 China Standard Time. Location: 50/f, office tower, convention plaza, 1 harbour road, wan chai, Hong Kongお知らせ • Apr 17National Medical Products Administration Grants Breakthrough-Therapy-Designated Drug for B7-H3-Targeted Antibody-Drug Conjugate Hs-20093 for InjectionHansoh Pharmaceutical Group Company Limited announced that, on April 17, 2025, the Group's self-developed B7-H3-targeted antibody-drug conjugate ("ADC") HS-20093 for injection has obtained approval to be included as Breakthrough-Therapy-Designated Drug by the National Medical Products Administration (" NMPA") of China, with the proposed indication for locally advanced or metastatic non-squamous non-small cell lung cancer without driver mutations, progressed or recurred following platinum-based chemotherapy.お知らせ • Apr 15Hansoh Pharmaceutical Group Company Limited Obtains Clinical Trial Approval for Hs-10529 TabletsThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, HS-10529 tablets, a Small Molecule Category I Innovative Drug targeting KRAS G12D self-developed by the Group, has obtained the Clinical Trial Approval issued by the National Medical Products Administration (NMPA) of China, which is intended to be investigated in clinical trials for advanced solid tumors (pancreatic cancer, colorectal cancer, non-small cell lung cancer, etc.) with KRAS G12D mutations.お知らせ • Apr 07+ 1 more updateHansoh Pharmaceutical Group Company Limited Obtains Clinical Trial Approval for HS-20108 for InjectionThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, innovative drug HS-20108 for injection, self-developed by the Group, has obtained the Clinical Trial Approval issued by the National Medical Products Administration (NMPA) of China recently, which is intended to be investigated in clinical trials for advanced solid tumors such as small cell lung cancer and neuroendocrine tumors.お知らせ • Mar 21Hansoh Pharmaceutical Group Company Limited Proposes Final Ordinary Dividend for the Year Ended December 31, 2024, Payable on July 25, 2025Hansoh Pharmaceutical Group Company Limited proposed final ordinary dividend of HKD 0.1353 per share for the year ended December 31, 2024. Ex-dividend date: July 3, 2025. Record date: July 9, 2025. Payment date: July 25, 2025.お知らせ • Mar 20TiumBio Co., Ltd.'s Partner Hansoh Pharma Expands Indications for Merigolix (HS-10518) with Initiation of ART (Assisted Reproductive Technology) DevelopmentTiumBio Co. Ltd. announced that its partner, Hansoh Pharma, has expanded the clinical indications of merigolix (Hansoh's code: HS-10518), an oral gonadotropin-releasing hormone receptor antagonist. Orally administered merigolix may be important in the control of premature endogenous LH surge and in reducing the cycle cancellation rate, with an improvement of pregnancy rate per cycle. Currently, in COS regimens, gonadotropin-re releasing hormone (GnRH) products are only available in injectable form, which caused the pain and relatively high cost. Meanwhile, merigolix is an oral GnRH receptor antagonist being developed for the treatment of endometriosis,uterine fibroids, and ART. TiumBio entered into a licensing agreement with Hansoh Pharma for merigolix for up to $170 million plus tiered royalties upon net sales. Under the terms of the agreement, Hansoh Pharma obtained exclusive rights to develop and commercialize merigolix in Greater China.お知らせ • Mar 10Hansoh Pharmaceutical Group Company Limited to Report Fiscal Year 2024 Results on Mar 21, 2025Hansoh Pharmaceutical Group Company Limited announced that they will report fiscal year 2024 results on Mar 21, 2025お知らせ • Mar 05Hansoh Pharmaceutical Group Company Limited Announces Acceptance of Second Biologics License Application by the National Medical Products AdministrationThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, on March 4, 2025, the second Biologics License Application (BLA) of XINYUE (Inebilizumab Injection) has been accepted by the National Medical Products Administration (the "NMPA"), which is for the treatment of immunoglobulin G4-related disease (IgG4-RD). On February 8, 2025, this indication has been included in the Priority Review and Approval Procedure by the NMPA. Inebilizumab is a targeted CD19 B cell-depleting antibody. On May 24, 2019, the Group entered into a license agreement with Viela Bio (Viela Bio was acquired by Horizon Therapeutics in 2021, which was acquired by Amgen in 2023), and has been granted an exclusive license to develop and commercialize the Product in China's mainland, Hong Kong and Macao. On March 14, 2022, the Product was approved to be launched in China by NMPA for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. In January 2023, the Product was included in the National Reimbursement Drug List for the first time, and this inclusion was successfully renewed in November 2024.お知らせ • Feb 25+ 1 more updateNational Medical Products Administration Grants Breakthrough-Therapy-Designated Drug for B7-H3-T Targeted Antibody-Drug Conjugate HS-20093 for Osteosarcoma of Hansoh Pharmaceutical Group Company LimitedThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that on February 25, 2025, the Group's self-developed B7-H3-targeted antibody-drug conjugate ("ADC") HS-20093 for injection has obtained approval to be included as Breakthrough-Therapy-Designated Drug by the National Medical Products Administration of China, with the proposed indication for the treatment of patients with osteosarcoma who have progressed on at least two prior lines of therapy. HS-20093 is an investigational B7-H3-targeted ADC composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to topoisomerase inhibitor (TOPOi) payload and being developed for the treatment of lung cancer, sarcoma, head and neck cancers and other solid tumors in multiple clinical trials in China, with the highest research stage being Phase III clinical trials. On November 1, 2024, the NMPA listed HS-20093 as a Breakthrough-Therapy-Designated Drug, with the indication being extensive-stage small-cell lung cancer (ES-SCLC) developed after standard first-line treatment (platinum doublet chemotherapy combined with immuno-therapy).お知らせ • Feb 10Hansoh Pharmaceutical Group Company Limited Announces New Indication of Xin Yue (Inebilizumab Injection) Included in Priority Review and Approval Procedure by the National Medical Products AdministrationThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, on February 8, 2025, based on the positive results from the global pivotal Phase III MITIGATE trial on XINYUE (Xin Yue ®?) (Inebilizumab Injection) (the Product), the new indication of the treatment of immunoglobulin G4-related disease (IgG4-RD) of the Product has been included in the Priority Review and Approval Procedure by the National Medical Products Administration (the NMPA).お知らせ • Jan 24Hansoh Pharmaceutical Group Company Limited Announces Changes to Company SecretaryThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, with effect from January 24, 2025, due to personal work arrangement, Ms. Tam Sze Wai Sara has tendered her resignation as a joint company secretary of the Company and ceased to be an authorized representative of the Company under Rule 3.05 of the Rule Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and the process agent of the Company in Hong Kong for the purpose of accepting service of process and notices on its behalf as required under Rule 19.05(2) of the Listing Rules and Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the "Process Agent"). Following the resignation of Ms. Tam, the Board announces that Ms. Wong Yuen Ki (" Ms. Wong") has been appointed as the joint company secretary with effect from January 24, 2025. Ms. Wong is a senior manager of corporate services of Tricor Services Limited. Ms. Wong possesses more than 10 years of experience in the company secretarial field. Ms. Wong is a Chartered Secretary, a Chartered Governance Professional and an associate of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute. Ms. Wong holds a degree of Bachelor of Business Administration in Corporate Administration and degree of Master of Corporate Governance from Hong Kong Metropolitan University. Ms. Wong possesses the academic or professional qualifications of a company secretary as required under Rule 3.28 of the Listing Rules. With effect from January 24, 2025, the joint company secretaries of the Company are Ms. Zhong Shengli and Ms. Wong.お知らせ • Nov 27Hansoh Pharmaceutical Group Company Limited Announces the Fifth New Drug Application of Ameile (Aumolertinib Mesilate Tablets) Was Accepted by the National Medical Products AdministrationHansoh Pharmaceutical Group Company Limited announced that, the fifth New Drug Application ("NDA") of the Group's innovative drug Ameile (A Mei Le ®?) (Aumolertinib Mesilate Tablets) has been accepted by the National Medical Products Administration of China ("NMPA"). The indication is that Ameile in combination with pemetrexed and platinum-based chemotherapy to be used as the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC") whose tumors have epidermal growth factor receptor (" EGFR") exon 19 deletions or exon 21 (L858R) mutations. . Ameile (Aumolertinib Mesilate Tablets) is the first innovative third-generation EGFR-TKI drug wholly developed in China. In March 2020, Ameile obtained approval for the treatment of patients with locally advanced or metastatic NSCLC with T790M mutation, who have progressed on or after EGFR-TKI therapy. In December 2021, Ameile obtained approval to be used as the first-line treatment for adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitute mutation positive. In July 2024, the NDA of Ameile for adjuvant therapy after tumor resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) mutations was accepted by the NMPA. In August 2024, the NDA of Ameile for the treatment in patients with locally advanced, unresectable, EGFR exon 19 deletions or exon 21 (L858R) mutations, NSCLC without progression following definitive platinum-based chemoradiotherapy was accepted by the NMPA.お知らせ • Nov 01Hansoh Pharmaceutical Group Company Limited Announces the NMPA Has Granted Breakthrough-Therapy-Designated Drug for B7-H3-Targeted Antibody-Drug Conjugate HS-20093The board of directors of Hansoh Pharmaceutical Group Company Limited announced that on November 1, 2024, the Group's self-developed B7-H3-targeted antibody-drug conjugate (‘ADC’) HS-20093 for injection has obtained approval to be included as Breakthrough-Therapy-Designated Drug by the National Medical Products Administration (‘NMPA’) of China, with the proposed indication being extensive stage small cell lung cancer (‘ES-SCLC’) developed after standard first-line treatment (platinum doublet chemotherapy combined with immuno-therapy).お知らせ • Oct 22Hansoh Pharmaceutical Group Company Limited Announces Phase III Registrational Trial AENEAS2 Evaluating Ameile in Combination with Chemotherapy for Patients with Locally Advanced or Metastatic EGFR-Mutated NSCLCThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that Phase III registrational trial AENEAS2 evaluating Ameile in combination with chemotherapy as first line therapy for patients with locally advanced (Stage IIIB~IIIC) or metastatic (Stage IV) epidermal growth factor receptor mutated non-small cell lung cancer met its primary endpoint of progression-free survival .AMEILE combined with chemotherapy demonstrated statistically significant and clinically meaningful improvement in PFS in patients with EGFR mutated advanced lung cancer. Detailed results of the study will be presented at upcoming medical conference and will be submitted to regulatory authority. Ameile (Aumolertinib Mesilate Tablets) is the first innovative third-generation EGFR-TKI drug wholly developed in China. In March 2020, Ameile obtained approval for the treatment of patients with locally advanced or metastatic NSCLC with T790M mutation, who have progressed on or after EGFR-TKI therapy, and was also successfully renewed in the 2022 National Reimbursement Drug List ("NRDL") in January 2023. In December 2021, Ameile obtained approval to be used as the first-line treatment for adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitute mutation positive, and has been included in the 2022 NRDL in January 2023. In July 2024, the New Drug Application ("NDA") of Ameile for adjuvant therapy after tumor resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations was accepted by the National Medical Products Administration (" NMPA "). In August 2024, the NDA of Ameile for the treatment in patients with locally advanced, unresectable, EGFR exon 19 deletions or exon 21 (L858R) mutations, NSCLC without progression following definitive platinum-based chemoradiotherapy was accepted by the NMPA.お知らせ • Aug 27Hansoh Pharmaceutical Group Company Limited Announces an Interim Dividend for the Six Months Ended June 30, 2024, Payable on 30 October 2024Hansoh Pharmaceutical Group Company Limited announced an interim dividend of HKD 0.201 per share for the six months ended June 30, 2024. Ex-dividend date is 20 September 2024. Record date is 25 September 2024. Payment date is 30 October 2024.お知らせ • Aug 15Hansoh Pharmaceutical Group Company Limited to Report First Half, 2024 Results on Aug 27, 2024Hansoh Pharmaceutical Group Company Limited announced that they will report first half, 2024 results on Aug 27, 2024お知らせ • Jul 20Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ammeile for the Adjuvant Treatment of Egfr Mutation-Positive Non-Small Cell Lung Cancer Accepted by the National Medical Products Administration of the People's Republic of ChinaThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that the New Drug Application of "Ameile" (A Mei Le ®?) for adjuvant therapy after tumor resection in patients with non-small cell lung cancer ("NSCLC") whose tumors have epidermal growth factor receptor ("EGFR") exon 19 deletions or exon 21 L858R mutations, was accepted by the National Medical Products Administration of the People's Republic of China. Ameile is a category 1 innovative drug developed by Jiangsu Hansoh Pharmaceutical Group Co. Ltd. ("J Jiang Su Hao Sen Yao Ye Ji Tuan You Xian Gong Si"), a subsidiary of the Company. The said application will be the third indication of Ameile.お知らせ • May 01Hansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 13, 2024Hansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 13, 2024, at 10:00 China Standard Time. Location: 10/F United Centre, 95 Queensway Admiralty Hong Kong Agenda: To receive and adopt the audited consolidated financial statements of the Company and the reports of the directors and auditors for the year ended December 31, 2023; to approve the payment of a final dividend for the year ended December 31, 2023; to re-elect Dr. Lyu Aifeng as executive director; to re-elect Mr. Lin Guoqiang as independent non-executive director; to authorize the board of directors to fix the respective directors' remuneration; to re-appoint Ernst & Young as auditors and to authorize the board of directors to fix their remuneration; and to transact other business.お知らせ • Apr 30Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024Hansoh Pharmaceutical Group Company Limited announced that, with effect from April 29, 2024, Ms. Li Yan Wing Rita (Ms. Li) has tendered her resignation as a joint company secretary of the company and ceased to be an authorized representative of the company (the Authorized Representative) under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the process agent of the company in Hong Kong for the purpose of accepting service of process and notices on its behalf as required under Rule 19.05(2) of the Listing Rules and Part 16 of the Companies Ordinance. Following the resignation of Ms. Li, the board announced that Ms. Tam Sze Wai Sara (Ms. Tam) has been appointed as a joint company secretary with effect from April 29, 2024. Ms. Tam is currently a manager of Corporate Services of Tricor Services Limited. She has over 10 years of experience in the corporate secretarial field and has been providing professional corporate services to Hong Kong listed companies as well as multinational, private and offshore companies. Ms. Tam is a Chartered Secretary, a Chartered Governance Professional and an associate of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute. Following the resignation of Ms. Li, she has also ceased to be an Authorized Representative and the Process Agent with effect from April 29, 2024. The Board announced that Ms. Tam, the newly appointed joint company secretary, has been appointed as an Authorized Representative and the Process Agent with effect from April 29, 2024.お知らせ • Apr 03Hansoh Pharmaceutical Group Company Limited, Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh Biomedical Technology Company Limited Receives Grant of A Clinical Trial Notice Issued by the National Medical Products Administration of the People's Republic of China to Be Used for the Treatment of Advanced Non-Small Cell Lung CancerThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS- 10504 tablets", a Category 1 innovative drug self-developed by Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh Biomedical Technology Company Limited, both being subsidiaries of the Company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of advanced non-small cell lung cancer. The specific indication will be determined after the completion of clinical research.お知らせ • Mar 15Hansoh Pharmaceutical Group Company Limited to Report Fiscal Year 2023 Results on Mar 26, 2024Hansoh Pharmaceutical Group Company Limited announced that they will report fiscal year 2023 results on Mar 26, 2024お知らせ • Jan 17Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of HS-10509 TabletsThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS-10509 tablets", a Category 1 innovative drug self-developed by Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh Biomedical Technology Company Limited, both being subsidiaries of the Company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of schizophrenia. The specific indication will be determined after the completion of clinical research.お知らせ • Nov 11Shanghai Hansoh Biomedical Technology Company Limited and Jiangsu Hansoh Pharmaceutical Group Company Limited Receives Clinical Trial NoticeThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS-10511 tablets", a Category 1 innovative drug self-developed by Shanghai Hansoh Biomedical Technology Company Limited ("Shang Hai Han Sen Sheng Wu Yi Yao Ke Ji You Xian Gong Si") and Jiangsu Hansoh Pharmaceutical Group Company Limited ("Jiang Su Hao Sen Yao Ye Ji Tuan You Xian Gong Si"), both being subsidiaries of the Company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of hypertrophic cardiomyopathy (HCM). The specific indication will be determined after the completion of clinical research.お知らせ • Oct 20Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of Hs-20106 InjectionsHansoh Pharmaceutical Group Company Limited announced that "HS-20106 Injections" (the "Product"), a Category 1 therapeutic biological product has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China. The specific indication will be determined after the completion of clinical research.お知らせ • Sep 26Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-20105"The board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS-20105", a Category 1 therapeutic biological product self-developed by Shanghai Hansoh Biomedical Technology Company Limited ("Shang Hai Han Sen Sheng Wu Yi Yao Ke Ji You Xian Gong Si") and Changzhou Hansoh Pharmaceutical Company Limited ("Ch Chang Zhou Heng Bang Yao Ye You Xian Gong Si"), both being subsidiaries of the Company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of advanced solid tumors. The specific indication will be determined after the completion of clinical research.お知らせ • Sep 02Hansoh Pharmaceutical Group Company Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 28 September 2023Hansoh Pharmaceutical Group Company Limited announced interim dividend of HKD 0.0707 per share for the six months ended June 30, 2023, payable on 28 September 2023. Record date to be 12 September 2023. Ex-dividend date to be 07 September 2023.お知らせ • Aug 22Hansoh Pharmaceutical Group Company Limited to Report Q2, 2023 Results on Aug 31, 2023Hansoh Pharmaceutical Group Company Limited announced that they will report Q2, 2023 results on Aug 31, 2023お知らせ • Jul 23Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ibrexafungerp Tablets Accepted by the National Medical Products AdministrationThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that the New Drug Application of "Ibrexafungerp Tablets" has been accepted by the National Medical Products Administration, and it is intended to be used for the treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (VVC). As disclosed in the announcement of the Company dated February 17, 2021, Hansoh (Shanghai) Healthtech Company Limited (Han Sen (Shang Hai) Jian Kang Ke Ji You Xian Gong Si) and Jiangsu Hansoh Pharmaceutical Group Company Limited (Jiang Su Hao Sen Yao Ye Ji Tuan You Xian Gong Si), both wholly-owned subsidiaries of the Company, obtained an exclusive license from SCYNEXIS Inc. to research, develop and commercialize Ibrexafungerp in the People's Republic of China (including Hong Kong, Macau and Taiwan).お知らせ • Jun 30Hansoh Pharmaceutical Group Company Limited Announces HS-10518 Capsules A Category 1 Innovative Drug, Has Been Granted A Clinical Trial NoticeThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS-10518 Capsules" (license-in as TU2670, the "Product"), a Category 1 innovative drug, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the management of moderate to severe pain associated with endometriosis and management of heavy menstrual bleeding associated with uterine leiomyomas.お知らせ • Jun 14Hansoh Pharmaceutical Group Company Limited Provides Update on Clinical Trial Notice of HS-10516 CapsulesThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS-10516 Capsules" (license-in as NKT2152, the "Product"), a Category 1 innovative drug, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of renal cell carcinoma (RCC).お知らせ • Jun 06Hansoh (Shanghai) Healthtech Company Limited Obtains an Exclusive License from Biotheus IncHansoh (Shanghai) Healthtech Company Limited obtained an exclusive license from Biotheus Inc. to develop and commercialize PM1080 within China (including Hong Kong, Macau and Taiwan). The board of directors (the "Board") of the Company announced that "HS-20117" (license-in as PM1080), a Category 1 innovative drug developed by the Group under the license from Biotheus, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of advanced solid tumor.お知らせ • May 06Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-10506 Tablets"The board of directors (the "Board") of Hansoh Pharmaceutical Group Company Limited announce that "HS-10506 tablets", a Category 1 innovative drug self- developed by Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh BioMedical Technology Company Limited, both being subsidiaries of the Company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of depression and insomnia. The specific indication will be determined after the completion of clinical research.株主還元HNSP.FUS PharmaceuticalsUS 市場7D0%5.3%1.1%1Y66.3%44.3%28.7%株主還元を見る業界別リターン: HNSP.F過去 1 年間で44.3 % の収益を上げたUS Pharmaceuticals業界を上回りました。リターン対市場: HNSP.F過去 1 年間で28.7 % の収益を上げたUS市場を上回りました。価格変動Is HNSP.F's price volatile compared to industry and market?HNSP.F volatilityHNSP.F Average Weekly Movementn/aPharmaceuticals Industry Average Movement9.9%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%安定した株価: HNSP.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のHNSP.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト19959,347Huijuan Zhongwww.hspharm.com投資持株会社である漢創薬集団有限公司は、中華人民共和国において医薬品の研究、開発、製造、販売を行っている。同社は、抗感染症、中枢神経系、がん、代謝性疾患などの治療分野や自己免疫疾患などの治療分野に製品を提供している。主な製品には、阿妹子、半夏厚朴湯、茯苓飲、沢飛、新台、新梅、外洛、丹能、普莱丹、恒武、麥苓大、恒仙、欧蘭寧、愛蘭寧、阿妹寧、心悦、聖洛来、福莱美、瑞宝、福莱迪、福莱瑞、普莱安錠などがある。グラクソ・スミスクライン・インテレクチュアル・プロパティ（No.4)Limitedとプラチナ製剤をベースとした化学療法施行中または施行後に病勢進行した広範囲小細胞肺がん（ES-SCLC）患者を対象としたHS-20089およびHS-20093の開発、製造、商業化に関するライセンス契約を締結している。と、二重特異性抗体薬物複合体製剤の開発・製造・商業化に関するライセンス契約、およびMerck Sharp & Dohme LLC（MSD）と、前臨床試験段階にある経口低分子グルカゴン様ペプチド-1（GLP-1）受容体作動薬であるHS-10535の開発・製造・商業化に関するライセンス契約を締結した。同社は1995年に設立され、中国の上海に本社を置いている。漢創薬集団有限公司はステラ・インフィニティ社の子会社である。もっと見るHansoh Pharmaceutical Group Company Limited 基礎のまとめHansoh Pharmaceutical Group の収益と売上を時価総額と比較するとどうか。HNSP.F 基礎統計学時価総額US$26.09b収益（TTM）US$817.64m売上高(TTM)US$2.21b31.9xPER（株価収益率11.8xP/SレシオHNSP.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計HNSP.F 損益計算書（TTM）収益CN¥15.03b売上原価CN¥1.52b売上総利益CN¥13.51bその他の費用CN¥7.95b収益CN¥5.56b直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）0.92グロス・マージン89.89%純利益率36.97%有利子負債／自己資本比率0.1%HNSP.F の長期的なパフォーマンスは？過去の実績と比較を見る配当金1.3%現在の配当利回り42%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 15:29終値2026/04/28 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Hansoh Pharmaceutical Group Company Limited 22 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。35 アナリスト機関Rebecca LiangBernsteinBo LiBofA Global ResearchJin ZhangChina International Capital Corporation Limited32 その他のアナリストを表示
お知らせ • Mar 18Hansoh Pharmaceutical Group Company Limited to Report Fiscal Year 2025 Results on Mar 29, 2026Hansoh Pharmaceutical Group Company Limited announced that they will report fiscal year 2025 results at 9:30 AM, China Standard Time on Mar 29, 2026
お知らせ • Feb 21Hansoh Pharmaceutical Group Company Limited Announces Approval in the European Union as MonotherapyThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, on February 12, 2026, Aumolertinib Mesylate Tablets, marketed as Ameile in China and Aumseqa outside China, the Group's innovative drug, has been approved in the European Union as monotherapy for: (i) the first-line treatment of adult patients with advanced non-small cell lung cancer ("NSCLC") whose tumours have epidermal growth factor receptor ("EGFR") exon 19 deletions or exon 21 (L858R) substitution mutations; and (ii) the treatment of adult patients with advanced EGFR T790M mutation-positive NSCLC. The approval by the European Commission (EC) follows the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
お知らせ • Jan 08Hansoh Pharmaceutical Group Company Limited Announces Drug Registration Approval of the Fifth Indication of Ameile (Aumolertinib Mesylate Tablets) Was Granted by the National Medical Products AdministrationThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, the Group's innovative drug Ameile (Aumolertinib Mesylate Tablets) has been granted drug registration approval by the National Medical Products Administration (" NMPA") of China, approving the addition of an indication: Ameile in combination with pemetrexed and platinum-based chemotherapy to be used as the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC") whose tumors have epidermal growth factor receptor (" EGFR") exon 19 deletions or exon 21 (L858R) mutations. This is the fifth indication of Ameile which has been approved.
お知らせ • Aug 21Hansoh Pharmaceutical Group Company Limited has filed a Follow-on Equity Offering in the amount of HKD 3.9204 billion.Hansoh Pharmaceutical Group Company Limited has filed a Follow-on Equity Offering in the amount of HKD 3.9204 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 108,000,000 Price\Range: HKD 36.3 Transaction Features: Subsequent Direct Listing
お知らせ • Aug 07Hansoh Pharmaceutical Group Company Limited to Report First Half, 2025 Results on Aug 18, 2025Hansoh Pharmaceutical Group Company Limited announced that they will report first half, 2025 results on Aug 18, 2025
お知らせ • Jun 05Hansoh Pharmaceutical Group Company Limited Announces Approval of Aumolertinib Mesilate Tablets by the Medicines and Healthcare Products Regulatory Agency for MarketingThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, Aumolertinib Mesilate Tablets (trade name in the UK: Aumseqa®?), the Group's innovative drug, has been approved by the Medicines and Healthcare Products Regulatory Agency ("MHRA") in the UK for marketing. Aumseqa®? as monotherapy is indicated for: the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC") with activating epidermal growth factor receptor (" EGFR") mutations, and the treatment of adult patients with locally Advanced or metastatic EGFR T790M mutation-positive NSCLC.
お知らせ • Mar 18Hansoh Pharmaceutical Group Company Limited to Report Fiscal Year 2025 Results on Mar 29, 2026Hansoh Pharmaceutical Group Company Limited announced that they will report fiscal year 2025 results at 9:30 AM, China Standard Time on Mar 29, 2026
お知らせ • Feb 21Hansoh Pharmaceutical Group Company Limited Announces Approval in the European Union as MonotherapyThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, on February 12, 2026, Aumolertinib Mesylate Tablets, marketed as Ameile in China and Aumseqa outside China, the Group's innovative drug, has been approved in the European Union as monotherapy for: (i) the first-line treatment of adult patients with advanced non-small cell lung cancer ("NSCLC") whose tumours have epidermal growth factor receptor ("EGFR") exon 19 deletions or exon 21 (L858R) substitution mutations; and (ii) the treatment of adult patients with advanced EGFR T790M mutation-positive NSCLC. The approval by the European Commission (EC) follows the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
お知らせ • Jan 08Hansoh Pharmaceutical Group Company Limited Announces Drug Registration Approval of the Fifth Indication of Ameile (Aumolertinib Mesylate Tablets) Was Granted by the National Medical Products AdministrationThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, the Group's innovative drug Ameile (Aumolertinib Mesylate Tablets) has been granted drug registration approval by the National Medical Products Administration (" NMPA") of China, approving the addition of an indication: Ameile in combination with pemetrexed and platinum-based chemotherapy to be used as the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC") whose tumors have epidermal growth factor receptor (" EGFR") exon 19 deletions or exon 21 (L858R) mutations. This is the fifth indication of Ameile which has been approved.
お知らせ • Aug 21Hansoh Pharmaceutical Group Company Limited has filed a Follow-on Equity Offering in the amount of HKD 3.9204 billion.Hansoh Pharmaceutical Group Company Limited has filed a Follow-on Equity Offering in the amount of HKD 3.9204 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 108,000,000 Price\Range: HKD 36.3 Transaction Features: Subsequent Direct Listing
お知らせ • Aug 07Hansoh Pharmaceutical Group Company Limited to Report First Half, 2025 Results on Aug 18, 2025Hansoh Pharmaceutical Group Company Limited announced that they will report first half, 2025 results on Aug 18, 2025
お知らせ • Jun 05Hansoh Pharmaceutical Group Company Limited Announces Approval of Aumolertinib Mesilate Tablets by the Medicines and Healthcare Products Regulatory Agency for MarketingThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, Aumolertinib Mesilate Tablets (trade name in the UK: Aumseqa®?), the Group's innovative drug, has been approved by the Medicines and Healthcare Products Regulatory Agency ("MHRA") in the UK for marketing. Aumseqa®? as monotherapy is indicated for: the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC") with activating epidermal growth factor receptor (" EGFR") mutations, and the treatment of adult patients with locally Advanced or metastatic EGFR T790M mutation-positive NSCLC.
お知らせ • May 31Hansoh Pharmaceutical Group Company Limited Announces the Third Biologics License Application of Xin Yue (Inebilizumab Injection) Has Been Accepted by the National Medical Products AdministrationThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, on May 29, 2025, the third biologics license application ("BLA") of XINYUE (Xin Yue ®?) (Inebilizumab Injection) (the "Product") has been accepted by the National Medical Products Administration (the "NMPA"), which is for the treatment of generalized myasthenia gravis (gMG) in adult patients.
お知らせ • May 30+ 1 more updateHansoh Pharmaceutical Group Company Limited Obtains Clinical Trial Approval Issued by the National Medical Products AdministrationThe board of directors of Hansoh Pharmaceutical Group Company Limited announce that, HS-10542 capsules, a Category 1 innovative drug self-developed by the Group, has obtained the Clinical Trial Approval issued by the National Medical Products Administration (NMPA) of China, which is intended to be investigated in clinical trials for paroxysmal nocturnal hemoglobinuria (PNH), and immunoglobulin A nephropathy (IgAN).
お知らせ • May 29+ 1 more updateHansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 20, 2025Hansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 20, 2025, at 10:00 China Standard Time. Location: 50/f, office tower, convention plaza, 1 harbour road, wan chai, Hong Kong
お知らせ • Apr 17National Medical Products Administration Grants Breakthrough-Therapy-Designated Drug for B7-H3-Targeted Antibody-Drug Conjugate Hs-20093 for InjectionHansoh Pharmaceutical Group Company Limited announced that, on April 17, 2025, the Group's self-developed B7-H3-targeted antibody-drug conjugate ("ADC") HS-20093 for injection has obtained approval to be included as Breakthrough-Therapy-Designated Drug by the National Medical Products Administration (" NMPA") of China, with the proposed indication for locally advanced or metastatic non-squamous non-small cell lung cancer without driver mutations, progressed or recurred following platinum-based chemotherapy.
お知らせ • Apr 15Hansoh Pharmaceutical Group Company Limited Obtains Clinical Trial Approval for Hs-10529 TabletsThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, HS-10529 tablets, a Small Molecule Category I Innovative Drug targeting KRAS G12D self-developed by the Group, has obtained the Clinical Trial Approval issued by the National Medical Products Administration (NMPA) of China, which is intended to be investigated in clinical trials for advanced solid tumors (pancreatic cancer, colorectal cancer, non-small cell lung cancer, etc.) with KRAS G12D mutations.
お知らせ • Apr 07+ 1 more updateHansoh Pharmaceutical Group Company Limited Obtains Clinical Trial Approval for HS-20108 for InjectionThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, innovative drug HS-20108 for injection, self-developed by the Group, has obtained the Clinical Trial Approval issued by the National Medical Products Administration (NMPA) of China recently, which is intended to be investigated in clinical trials for advanced solid tumors such as small cell lung cancer and neuroendocrine tumors.
お知らせ • Mar 21Hansoh Pharmaceutical Group Company Limited Proposes Final Ordinary Dividend for the Year Ended December 31, 2024, Payable on July 25, 2025Hansoh Pharmaceutical Group Company Limited proposed final ordinary dividend of HKD 0.1353 per share for the year ended December 31, 2024. Ex-dividend date: July 3, 2025. Record date: July 9, 2025. Payment date: July 25, 2025.
お知らせ • Mar 20TiumBio Co., Ltd.'s Partner Hansoh Pharma Expands Indications for Merigolix (HS-10518) with Initiation of ART (Assisted Reproductive Technology) DevelopmentTiumBio Co. Ltd. announced that its partner, Hansoh Pharma, has expanded the clinical indications of merigolix (Hansoh's code: HS-10518), an oral gonadotropin-releasing hormone receptor antagonist. Orally administered merigolix may be important in the control of premature endogenous LH surge and in reducing the cycle cancellation rate, with an improvement of pregnancy rate per cycle. Currently, in COS regimens, gonadotropin-re releasing hormone (GnRH) products are only available in injectable form, which caused the pain and relatively high cost. Meanwhile, merigolix is an oral GnRH receptor antagonist being developed for the treatment of endometriosis,uterine fibroids, and ART. TiumBio entered into a licensing agreement with Hansoh Pharma for merigolix for up to $170 million plus tiered royalties upon net sales. Under the terms of the agreement, Hansoh Pharma obtained exclusive rights to develop and commercialize merigolix in Greater China.
お知らせ • Mar 10Hansoh Pharmaceutical Group Company Limited to Report Fiscal Year 2024 Results on Mar 21, 2025Hansoh Pharmaceutical Group Company Limited announced that they will report fiscal year 2024 results on Mar 21, 2025
お知らせ • Mar 05Hansoh Pharmaceutical Group Company Limited Announces Acceptance of Second Biologics License Application by the National Medical Products AdministrationThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, on March 4, 2025, the second Biologics License Application (BLA) of XINYUE (Inebilizumab Injection) has been accepted by the National Medical Products Administration (the "NMPA"), which is for the treatment of immunoglobulin G4-related disease (IgG4-RD). On February 8, 2025, this indication has been included in the Priority Review and Approval Procedure by the NMPA. Inebilizumab is a targeted CD19 B cell-depleting antibody. On May 24, 2019, the Group entered into a license agreement with Viela Bio (Viela Bio was acquired by Horizon Therapeutics in 2021, which was acquired by Amgen in 2023), and has been granted an exclusive license to develop and commercialize the Product in China's mainland, Hong Kong and Macao. On March 14, 2022, the Product was approved to be launched in China by NMPA for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. In January 2023, the Product was included in the National Reimbursement Drug List for the first time, and this inclusion was successfully renewed in November 2024.
お知らせ • Feb 25+ 1 more updateNational Medical Products Administration Grants Breakthrough-Therapy-Designated Drug for B7-H3-T Targeted Antibody-Drug Conjugate HS-20093 for Osteosarcoma of Hansoh Pharmaceutical Group Company LimitedThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that on February 25, 2025, the Group's self-developed B7-H3-targeted antibody-drug conjugate ("ADC") HS-20093 for injection has obtained approval to be included as Breakthrough-Therapy-Designated Drug by the National Medical Products Administration of China, with the proposed indication for the treatment of patients with osteosarcoma who have progressed on at least two prior lines of therapy. HS-20093 is an investigational B7-H3-targeted ADC composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to topoisomerase inhibitor (TOPOi) payload and being developed for the treatment of lung cancer, sarcoma, head and neck cancers and other solid tumors in multiple clinical trials in China, with the highest research stage being Phase III clinical trials. On November 1, 2024, the NMPA listed HS-20093 as a Breakthrough-Therapy-Designated Drug, with the indication being extensive-stage small-cell lung cancer (ES-SCLC) developed after standard first-line treatment (platinum doublet chemotherapy combined with immuno-therapy).
お知らせ • Feb 10Hansoh Pharmaceutical Group Company Limited Announces New Indication of Xin Yue (Inebilizumab Injection) Included in Priority Review and Approval Procedure by the National Medical Products AdministrationThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, on February 8, 2025, based on the positive results from the global pivotal Phase III MITIGATE trial on XINYUE (Xin Yue ®?) (Inebilizumab Injection) (the Product), the new indication of the treatment of immunoglobulin G4-related disease (IgG4-RD) of the Product has been included in the Priority Review and Approval Procedure by the National Medical Products Administration (the NMPA).
お知らせ • Jan 24Hansoh Pharmaceutical Group Company Limited Announces Changes to Company SecretaryThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, with effect from January 24, 2025, due to personal work arrangement, Ms. Tam Sze Wai Sara has tendered her resignation as a joint company secretary of the Company and ceased to be an authorized representative of the Company under Rule 3.05 of the Rule Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and the process agent of the Company in Hong Kong for the purpose of accepting service of process and notices on its behalf as required under Rule 19.05(2) of the Listing Rules and Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the "Process Agent"). Following the resignation of Ms. Tam, the Board announces that Ms. Wong Yuen Ki (" Ms. Wong") has been appointed as the joint company secretary with effect from January 24, 2025. Ms. Wong is a senior manager of corporate services of Tricor Services Limited. Ms. Wong possesses more than 10 years of experience in the company secretarial field. Ms. Wong is a Chartered Secretary, a Chartered Governance Professional and an associate of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute. Ms. Wong holds a degree of Bachelor of Business Administration in Corporate Administration and degree of Master of Corporate Governance from Hong Kong Metropolitan University. Ms. Wong possesses the academic or professional qualifications of a company secretary as required under Rule 3.28 of the Listing Rules. With effect from January 24, 2025, the joint company secretaries of the Company are Ms. Zhong Shengli and Ms. Wong.
お知らせ • Nov 27Hansoh Pharmaceutical Group Company Limited Announces the Fifth New Drug Application of Ameile (Aumolertinib Mesilate Tablets) Was Accepted by the National Medical Products AdministrationHansoh Pharmaceutical Group Company Limited announced that, the fifth New Drug Application ("NDA") of the Group's innovative drug Ameile (A Mei Le ®?) (Aumolertinib Mesilate Tablets) has been accepted by the National Medical Products Administration of China ("NMPA"). The indication is that Ameile in combination with pemetrexed and platinum-based chemotherapy to be used as the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC") whose tumors have epidermal growth factor receptor (" EGFR") exon 19 deletions or exon 21 (L858R) mutations. . Ameile (Aumolertinib Mesilate Tablets) is the first innovative third-generation EGFR-TKI drug wholly developed in China. In March 2020, Ameile obtained approval for the treatment of patients with locally advanced or metastatic NSCLC with T790M mutation, who have progressed on or after EGFR-TKI therapy. In December 2021, Ameile obtained approval to be used as the first-line treatment for adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitute mutation positive. In July 2024, the NDA of Ameile for adjuvant therapy after tumor resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) mutations was accepted by the NMPA. In August 2024, the NDA of Ameile for the treatment in patients with locally advanced, unresectable, EGFR exon 19 deletions or exon 21 (L858R) mutations, NSCLC without progression following definitive platinum-based chemoradiotherapy was accepted by the NMPA.
お知らせ • Nov 01Hansoh Pharmaceutical Group Company Limited Announces the NMPA Has Granted Breakthrough-Therapy-Designated Drug for B7-H3-Targeted Antibody-Drug Conjugate HS-20093The board of directors of Hansoh Pharmaceutical Group Company Limited announced that on November 1, 2024, the Group's self-developed B7-H3-targeted antibody-drug conjugate (‘ADC’) HS-20093 for injection has obtained approval to be included as Breakthrough-Therapy-Designated Drug by the National Medical Products Administration (‘NMPA’) of China, with the proposed indication being extensive stage small cell lung cancer (‘ES-SCLC’) developed after standard first-line treatment (platinum doublet chemotherapy combined with immuno-therapy).
お知らせ • Oct 22Hansoh Pharmaceutical Group Company Limited Announces Phase III Registrational Trial AENEAS2 Evaluating Ameile in Combination with Chemotherapy for Patients with Locally Advanced or Metastatic EGFR-Mutated NSCLCThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that Phase III registrational trial AENEAS2 evaluating Ameile in combination with chemotherapy as first line therapy for patients with locally advanced (Stage IIIB~IIIC) or metastatic (Stage IV) epidermal growth factor receptor mutated non-small cell lung cancer met its primary endpoint of progression-free survival .AMEILE combined with chemotherapy demonstrated statistically significant and clinically meaningful improvement in PFS in patients with EGFR mutated advanced lung cancer. Detailed results of the study will be presented at upcoming medical conference and will be submitted to regulatory authority. Ameile (Aumolertinib Mesilate Tablets) is the first innovative third-generation EGFR-TKI drug wholly developed in China. In March 2020, Ameile obtained approval for the treatment of patients with locally advanced or metastatic NSCLC with T790M mutation, who have progressed on or after EGFR-TKI therapy, and was also successfully renewed in the 2022 National Reimbursement Drug List ("NRDL") in January 2023. In December 2021, Ameile obtained approval to be used as the first-line treatment for adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitute mutation positive, and has been included in the 2022 NRDL in January 2023. In July 2024, the New Drug Application ("NDA") of Ameile for adjuvant therapy after tumor resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations was accepted by the National Medical Products Administration (" NMPA "). In August 2024, the NDA of Ameile for the treatment in patients with locally advanced, unresectable, EGFR exon 19 deletions or exon 21 (L858R) mutations, NSCLC without progression following definitive platinum-based chemoradiotherapy was accepted by the NMPA.
お知らせ • Aug 27Hansoh Pharmaceutical Group Company Limited Announces an Interim Dividend for the Six Months Ended June 30, 2024, Payable on 30 October 2024Hansoh Pharmaceutical Group Company Limited announced an interim dividend of HKD 0.201 per share for the six months ended June 30, 2024. Ex-dividend date is 20 September 2024. Record date is 25 September 2024. Payment date is 30 October 2024.
お知らせ • Aug 15Hansoh Pharmaceutical Group Company Limited to Report First Half, 2024 Results on Aug 27, 2024Hansoh Pharmaceutical Group Company Limited announced that they will report first half, 2024 results on Aug 27, 2024
お知らせ • Jul 20Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ammeile for the Adjuvant Treatment of Egfr Mutation-Positive Non-Small Cell Lung Cancer Accepted by the National Medical Products Administration of the People's Republic of ChinaThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that the New Drug Application of "Ameile" (A Mei Le ®?) for adjuvant therapy after tumor resection in patients with non-small cell lung cancer ("NSCLC") whose tumors have epidermal growth factor receptor ("EGFR") exon 19 deletions or exon 21 L858R mutations, was accepted by the National Medical Products Administration of the People's Republic of China. Ameile is a category 1 innovative drug developed by Jiangsu Hansoh Pharmaceutical Group Co. Ltd. ("J Jiang Su Hao Sen Yao Ye Ji Tuan You Xian Gong Si"), a subsidiary of the Company. The said application will be the third indication of Ameile.
お知らせ • May 01Hansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 13, 2024Hansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 13, 2024, at 10:00 China Standard Time. Location: 10/F United Centre, 95 Queensway Admiralty Hong Kong Agenda: To receive and adopt the audited consolidated financial statements of the Company and the reports of the directors and auditors for the year ended December 31, 2023; to approve the payment of a final dividend for the year ended December 31, 2023; to re-elect Dr. Lyu Aifeng as executive director; to re-elect Mr. Lin Guoqiang as independent non-executive director; to authorize the board of directors to fix the respective directors' remuneration; to re-appoint Ernst & Young as auditors and to authorize the board of directors to fix their remuneration; and to transact other business.
お知らせ • Apr 30Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024Hansoh Pharmaceutical Group Company Limited announced that, with effect from April 29, 2024, Ms. Li Yan Wing Rita (Ms. Li) has tendered her resignation as a joint company secretary of the company and ceased to be an authorized representative of the company (the Authorized Representative) under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the process agent of the company in Hong Kong for the purpose of accepting service of process and notices on its behalf as required under Rule 19.05(2) of the Listing Rules and Part 16 of the Companies Ordinance. Following the resignation of Ms. Li, the board announced that Ms. Tam Sze Wai Sara (Ms. Tam) has been appointed as a joint company secretary with effect from April 29, 2024. Ms. Tam is currently a manager of Corporate Services of Tricor Services Limited. She has over 10 years of experience in the corporate secretarial field and has been providing professional corporate services to Hong Kong listed companies as well as multinational, private and offshore companies. Ms. Tam is a Chartered Secretary, a Chartered Governance Professional and an associate of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute. Following the resignation of Ms. Li, she has also ceased to be an Authorized Representative and the Process Agent with effect from April 29, 2024. The Board announced that Ms. Tam, the newly appointed joint company secretary, has been appointed as an Authorized Representative and the Process Agent with effect from April 29, 2024.
お知らせ • Apr 03Hansoh Pharmaceutical Group Company Limited, Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh Biomedical Technology Company Limited Receives Grant of A Clinical Trial Notice Issued by the National Medical Products Administration of the People's Republic of China to Be Used for the Treatment of Advanced Non-Small Cell Lung CancerThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS- 10504 tablets", a Category 1 innovative drug self-developed by Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh Biomedical Technology Company Limited, both being subsidiaries of the Company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of advanced non-small cell lung cancer. The specific indication will be determined after the completion of clinical research.
お知らせ • Mar 15Hansoh Pharmaceutical Group Company Limited to Report Fiscal Year 2023 Results on Mar 26, 2024Hansoh Pharmaceutical Group Company Limited announced that they will report fiscal year 2023 results on Mar 26, 2024
お知らせ • Jan 17Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of HS-10509 TabletsThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS-10509 tablets", a Category 1 innovative drug self-developed by Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh Biomedical Technology Company Limited, both being subsidiaries of the Company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of schizophrenia. The specific indication will be determined after the completion of clinical research.
お知らせ • Nov 11Shanghai Hansoh Biomedical Technology Company Limited and Jiangsu Hansoh Pharmaceutical Group Company Limited Receives Clinical Trial NoticeThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS-10511 tablets", a Category 1 innovative drug self-developed by Shanghai Hansoh Biomedical Technology Company Limited ("Shang Hai Han Sen Sheng Wu Yi Yao Ke Ji You Xian Gong Si") and Jiangsu Hansoh Pharmaceutical Group Company Limited ("Jiang Su Hao Sen Yao Ye Ji Tuan You Xian Gong Si"), both being subsidiaries of the Company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of hypertrophic cardiomyopathy (HCM). The specific indication will be determined after the completion of clinical research.
お知らせ • Oct 20Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of Hs-20106 InjectionsHansoh Pharmaceutical Group Company Limited announced that "HS-20106 Injections" (the "Product"), a Category 1 therapeutic biological product has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China. The specific indication will be determined after the completion of clinical research.
お知らせ • Sep 26Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-20105"The board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS-20105", a Category 1 therapeutic biological product self-developed by Shanghai Hansoh Biomedical Technology Company Limited ("Shang Hai Han Sen Sheng Wu Yi Yao Ke Ji You Xian Gong Si") and Changzhou Hansoh Pharmaceutical Company Limited ("Ch Chang Zhou Heng Bang Yao Ye You Xian Gong Si"), both being subsidiaries of the Company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of advanced solid tumors. The specific indication will be determined after the completion of clinical research.
お知らせ • Sep 02Hansoh Pharmaceutical Group Company Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 28 September 2023Hansoh Pharmaceutical Group Company Limited announced interim dividend of HKD 0.0707 per share for the six months ended June 30, 2023, payable on 28 September 2023. Record date to be 12 September 2023. Ex-dividend date to be 07 September 2023.
お知らせ • Aug 22Hansoh Pharmaceutical Group Company Limited to Report Q2, 2023 Results on Aug 31, 2023Hansoh Pharmaceutical Group Company Limited announced that they will report Q2, 2023 results on Aug 31, 2023
お知らせ • Jul 23Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ibrexafungerp Tablets Accepted by the National Medical Products AdministrationThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that the New Drug Application of "Ibrexafungerp Tablets" has been accepted by the National Medical Products Administration, and it is intended to be used for the treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (VVC). As disclosed in the announcement of the Company dated February 17, 2021, Hansoh (Shanghai) Healthtech Company Limited (Han Sen (Shang Hai) Jian Kang Ke Ji You Xian Gong Si) and Jiangsu Hansoh Pharmaceutical Group Company Limited (Jiang Su Hao Sen Yao Ye Ji Tuan You Xian Gong Si), both wholly-owned subsidiaries of the Company, obtained an exclusive license from SCYNEXIS Inc. to research, develop and commercialize Ibrexafungerp in the People's Republic of China (including Hong Kong, Macau and Taiwan).
お知らせ • Jun 30Hansoh Pharmaceutical Group Company Limited Announces HS-10518 Capsules A Category 1 Innovative Drug, Has Been Granted A Clinical Trial NoticeThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS-10518 Capsules" (license-in as TU2670, the "Product"), a Category 1 innovative drug, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the management of moderate to severe pain associated with endometriosis and management of heavy menstrual bleeding associated with uterine leiomyomas.
お知らせ • Jun 14Hansoh Pharmaceutical Group Company Limited Provides Update on Clinical Trial Notice of HS-10516 CapsulesThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS-10516 Capsules" (license-in as NKT2152, the "Product"), a Category 1 innovative drug, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of renal cell carcinoma (RCC).
お知らせ • Jun 06Hansoh (Shanghai) Healthtech Company Limited Obtains an Exclusive License from Biotheus IncHansoh (Shanghai) Healthtech Company Limited obtained an exclusive license from Biotheus Inc. to develop and commercialize PM1080 within China (including Hong Kong, Macau and Taiwan). The board of directors (the "Board") of the Company announced that "HS-20117" (license-in as PM1080), a Category 1 innovative drug developed by the Group under the license from Biotheus, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of advanced solid tumor.
お知らせ • May 06Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-10506 Tablets"The board of directors (the "Board") of Hansoh Pharmaceutical Group Company Limited announce that "HS-10506 tablets", a Category 1 innovative drug self- developed by Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh BioMedical Technology Company Limited, both being subsidiaries of the Company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of depression and insomnia. The specific indication will be determined after the completion of clinical research.
